Cannabis Bioscience International Holdings, Inc. files a late notice for its quarterly report, citing an uncompleted annual audit and the termination of its clinical-trial business.
SEC EDGAR, 2026-10-16: NT 10-Q — "12b-25"
Cannabis Bioscience International Holdings, Inc. files a late notice for its quarterly report, citing an uncompleted annual audit and the termination of its clinical-trial business.
Company: Cannabis Bioscience International Holdings, Inc. (CBIH) Filed: October 16, 2026, NT 10-Q (Item 12b-25) Phrase: "12b-25" — "If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed." What the filing says: The company cannot complete and analyze its quarterly report on Form 10-Q for the period ended August 31, 2026, because it has not yet completed the audit of its financial statements for the fiscal year ended May 31, 2026. The company also notes that its annual report on Form 10-K for the year ended May 31, 2026, remains unfiled. For the quarter ended August 31, 2026, the company anticipates reporting revenues and gross profit of approximately $1,000, down from $24,200 and $16,057 respectively in the prior-year quarter, principally because its clinical-trial business was terminated on July 31, 2026. It expects a net loss of approximately $172,000 compared to a net loss of $82,645 in the prior-year quarter. The company states it cannot assure that the quarterly reports will be filed within the extension period. Two ways it goes: A. The company completes its annual audit and files its late annual and quarterly reports. B. The company fails to file its delinquent reports and faces potential regulatory actions or delisting. Next date: October 21, 2026 (the five-calendar-day extension deadline for Form 10-Q under Rule 12b-25) Watch: The filing of the company's Form 10-K for the fiscal year ended May 31, 2026, and Form 10-Q for the quarter ended August 31, 2026.